Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Grundman

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|December 25, 2018
A randomized, single ascending dose study of intravenous BIIB092 in healthy participantsIrfan A Qureshi, Giridhar Tirucherai, Michael K Ahlijanian, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentMichael Grundman, Susan Catalano, Mary E Hamby, et al.
Archives of Neurology|February 13, 2003
Estrogen levels do not correlate with improvement in cognitionLeon J Thal, Ronald G Thomas, Ruth Mulnard, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentAlireza Faridar, Nazaret Gamez, Michael Grundman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 5, 2012
Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trialsJesse M Cedarbaum, Mark Jaros, Chito Hernandez, et al.
Annals of Neurology|July 2, 2003
Laboratory investigations and treatment in frontotemporal dementiaFlorence Pasquier, Toshiya Fukui, Marie Sarazin, et al.
International Journal of Molecular Sciences|April 13, 2023
Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative DiseasesBritney N Lizama, Jennifer Kahle, Susan M Catalano, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2012
The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trialsNandini Raghavan, Mahesh N Samtani, Michael Farnum, et al.
Archives of Neurology|April 5, 2012
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer diseaseKaj Blennow, Henrik Zetterberg, Juha O Rinne, et al.
Alzheimer Disease and Associated Disorders|May 28, 2010
A single ascending dose study of bapineuzumab in patients with Alzheimer diseaseRonald S Black, Reisa A Sperling, Beth Safirstein, et al.
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
Alzheimer'S & Dementia (New York, N. Y.)|December 25, 2018
A randomized, single ascending dose study of intravenous BIIB092 in healthy participantsIrfan A Qureshi, Giridhar Tirucherai, Michael K Ahlijanian, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentMichael Grundman, Susan Catalano, Mary E Hamby, et al.
Archives of Neurology|February 13, 2003
Estrogen levels do not correlate with improvement in cognitionLeon J Thal, Ronald G Thomas, Ruth Mulnard, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Drug DevelopmentAlireza Faridar, Nazaret Gamez, Michael Grundman, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 5, 2012
Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trialsJesse M Cedarbaum, Mark Jaros, Chito Hernandez, et al.
Annals of Neurology|July 2, 2003
Laboratory investigations and treatment in frontotemporal dementiaFlorence Pasquier, Toshiya Fukui, Marie Sarazin, et al.
International Journal of Molecular Sciences|April 13, 2023
Sigma-2 Receptors-From Basic Biology to Therapeutic Target: A Focus on Age-Related Degenerative DiseasesBritney N Lizama, Jennifer Kahle, Susan M Catalano, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 7, 2012
The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trialsNandini Raghavan, Mahesh N Samtani, Michael Farnum, et al.
Archives of Neurology|April 5, 2012
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer diseaseKaj Blennow, Henrik Zetterberg, Juha O Rinne, et al.
Alzheimer Disease and Associated Disorders|May 28, 2010
A single ascending dose study of bapineuzumab in patients with Alzheimer diseaseRonald S Black, Reisa A Sperling, Beth Safirstein, et al.
Pageof 8